s-riva-d-amphetamine | 851086-92-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: s-riva-d-amphetamine
• 英文别名: S-rivastigmine-d-amphetamine；3-((S)-1-(dimethylamino)ethyl)phenyl(S)-1-phenylpropan-2-ylcarbamate hydrochloride；[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-[(2S)-1-phenylpropan-2-yl]carbamate
• CAS: 851086-92-5
• 化学式: C₂₀H₂₆N₂O₂
• 分子量: 326.439
• InChiKey: HKJROXHSAHRDAO-HOTGVXAUSA-N

物化性质

• 沸点：
  424.1±45.0 °C(Predicted)
• 密度：
  1.074±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  s-riva-d-amphetamine 在 盐酸 作用下， 以 乙醚 为溶剂， 以100%的产率得到[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-[(2S)-1-phenylpropan-2-yl]carbamate;hydrochloride
  参考文献：
  名称：

  COMPOSITIONS OF CHOLINESTERASE INHIBITORS

  摘要：

  本发明涉及与3-((S)-1-(二甲基氨基)乙基)苯基甲基-((R)-1-苯基丙烷-2基)氨基甲酸酯及其药用可接受盐形式相关的合成的组合物、使用方法和过程，包括富马酸盐。本发明还涉及3-((S)-1-(二甲基氨基)乙基)苯基甲基-((R)-1-苯基丙烷-2基)氨基甲酸酯的新型形态多晶形态，其具有独特的X射线衍射图案和差示扫描量热分析剖面，以及独特的晶体结构。

  公开号：

  US20100256229A1
• 作为产物：
  描述：

  、 右旋苯丙胺 以 乙酸乙酯 为溶剂， 生成 s-riva-d-amphetamine
  参考文献：
  名称：

  COMPOSITIONS OF CHOLINESTERASE INHIBITORS

  摘要：

  本发明涉及与3-((S)-1-(二甲基氨基)乙基)苯基甲基-((R)-1-苯基丙烷-2基)氨基甲酸酯及其药用可接受盐形式相关的合成的组合物、使用方法和过程，包括富马酸盐。本发明还涉及3-((S)-1-(二甲基氨基)乙基)苯基甲基-((R)-1-苯基丙烷-2基)氨基甲酸酯的新型形态多晶形态，其具有独特的X射线衍射图案和差示扫描量热分析剖面，以及独特的晶体结构。

  公开号：

  US20100256229A1

文献信息

• Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
  申请人：Verheijen C. Jeroen

  公开号：US20050096387A1

  公开（公告）日：2005-05-05

  Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.

  碳酰基酯抑制胆碱酯酶活性，水解后释放出药理活性成分。在一种实施例中，碳酰基酯具有以下结构：其中A选自无取代芳基、取代芳基、无取代杂环芳基和取代杂环芳基的群组。碳酰基酯用于治疗个体的方法中。通过水解碳酰基酯获得的药理活性成分可以治疗例如神经系统疾病、胆碱能缺乏以及与药理活性成分缺乏相关的疾病或病症，例如乙酰胆碱。
• [EN] STIGMINE CONJUGATES FOR SUBSTANCE USE DISORDERS<br/>[FR] CONJUGUÉS DE STIGMINE POUR DES TROUBLES DE TOXICOMANIE
  申请人：COLUCID PHARMACEUTICALS INC

  公开号：WO2010009316A1

  公开（公告）日：2010-01-21

  The invention relates to methods for the treatment or prevention of substance use disorders.

  该发明涉及用于治疗或预防物质使用障碍的方法。
• Novel carbamate cholinesterase inhibitors that release biologically active amines following enzyme inhibition
  作者：Jeroen C. Verheijen、Kjesten A. Wiig、Shoucheng Du、Stacie L. Connors、Ashley N. Martin、Jennifer P. Ferreira、Vladimir I. Slepnev、Ulrike Kochendörfer

  DOI：10.1016/j.bmcl.2009.04.089

  日期：2009.6

  Conjugation of the phenol derived from rivastigmine with amphetamines gave access to novel carbamate cholinesterase inhibitors. All compounds possessed increased affinity and selectivity for AChE compared to rivastigmine and were orally bioavailable. Compound 4a, incorporating d-amphetamine, caused significant inhibition of cholinesterase in vivo at doses that were well tolerated. Release of amphetamine from 4a was demonstrated following in vitro and in vivo inhibition of cholinesterase. Compound 4a was also effective in alleviating scopolamine induced amnesia in a rat passive avoidance model. (C) 2009 Elsevier Ltd. All rights reserved.
• Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents
  申请人：Verheijen C. Jeroen

  公开号：US20070275959A1

  公开（公告）日：2007-11-29

  Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: Formula (I) wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.
• Methods for promoting wakefulness
  申请人：Rupniak Nadia M.J.

  公开号：US20090048229A1

  公开（公告）日：2009-02-19

  The present invention relates to methods of promoting wakefulness in an individual by administering a carbamoyl ester or a pharmaceutically acceptable salt thereof.